Table 2.
Characterisation of study group (n = 72) compared to group of counselled women for fertility preservation (n = 162) at the time of the questionnaire mailing and rounded data of the FertiPROTEKT network from 2007–2015 [1]
| All women counselled for fertility preservation 2007–2015 | Study group of women (answered questionnaire) in 2016 | Statistical analysis (p value) | Data of the ‘FertiPROTEKT’ network 2007–2015 | |
|---|---|---|---|---|
| Number of women | 162 | 72 | – | ≈ 7150 |
| Mean age in years at counselling /diagnosis of cancer | 26.7 ± 6.9 (6–40) | 27.1 ± 6.3 (15–39) | 0.689 | 28 |
| Mean age in years at questionnaire study (8/2016) | 30.6 ± 7.2 (8–48) | 30.4 ± 6.4 (17–44) | 0.807 | – |
| Time interval between counselling and time of contact (sent and/or answered questionnaire) | 3.8 ± 2.4 (1–9) | 3.1 ± 2.2 (1–9) | 0.064 | – |
| In % (n =) | In % (n =) | Statistical analysis (p value) | In % | |
|---|---|---|---|---|
| Most frequent diagnoses | ||||
| Breast cancer | 35.2 (57) | 37.5 (27) | 0.735 | 37 |
| Hodgkin lymphoma | 26.5 (43) | 36.1 (26) | 0.154 | 26 (incl. NHL) |
| Autoimmune diseases | 9.3 (15) | 1.4 (1) | 0.004 | 7 |
| Non-Hodgkin lymphoma | 7.4 (12) | 8.3 (6) | 0.807 | Not determined |
| Leukaemia | 5.6 (9) | 6.9 (5) | 0.681 | 5 |
| Ewing sarcoma | 3.1 (5) | 4.2 (3) | 0.676 | Not determined |
| Fertility preservation methodsa | ||||
| GnRH | 58.0 (94) | 62.5 (45) | 0.552 | 47 |
| Cryopreservation of ovarian tissue | 40.1 (65) | 50.0 (36) | 0.161 | 33 |
| Cryopreservation of oocytes | 1.9 (3) | 0 | 0.083 | 17 |
| Transposition of ovaries | 0.6 (1) | 1.4 (1) | 0.556 | 2 |
aMultiple treatment possible, most often GnRH agonists in combination with cryopreservation of ovarian tissue